Glucagon-like peptide-1 agonism - GLP-1, common in obesity medicines - is not essential to weight management, according to preclinical research led by Richard DiMarchi and Matthias Tschöp, with funding from their startup company Bluewater Biosciences.
“I know this ‘if you go off the diet plan you gain weight’ argument is big in anti diet plans, but…’”
I get that gol1s help people regulate their caloric intake. Don’t get me wrong.
But acting like they’re some miracle when they’re not is counter productive, particularly given that the core issue is ultimately behavioral in the first place.
People who’ve gotten to obesity have done so are more likely to revert to the same habits that led to it in the first place. Unless there’s something fairly radical about their lifestyle.
For me that change was finding a few gymbro friends who both cared enough to keep me going and genuinely celebrated my losses (and gains, weightlifting was part of the exercise thing.)
I’m not a gymbro, and I never will be, but being around them is sort of like a smoker finding new friends who don’t smoke. It makes it easier.
The other more important change was therapy. Lifelong habits don’t change easily, and therapy makes that much easier.
The point being here that GPL1 is not the only way to get there; and in terms of society’s health, almost certainly not the best solution. (That solution would require prevention, and corporations don’t like that.)